Peter Szecsody
Glattbrugg, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: March 11, 2026
Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a study.
Journal: Orphanet journal of rare diseases
Published: April 03, 2025
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry.
Journal: Journal of cardiac failure
Published: June 05, 2024
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
Journal: European heart journal
Published: March 21, 2022
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
Journal: European journal of heart failure
Published: October 05, 2021
Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction.
Journal: European journal of heart failure
Published: August 05, 2020
Effects of Serelaxin in Patients with Acute Heart Failure.
Journal: The New England journal of medicine
Published: August 22, 2019
Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial.
Journal: American heart journal
Published: January 30, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026